A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension

Singh, Thakar; Rohit, Manoj Kumar; Grover, Anil; Malhotra, Samir; Vijayvergiya, Rajesh

doi:10.1016/j.ahj.2005.09.006

Cited by 222 publications

(118 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sildenafil is a selective inhibitor of 5 'phosphodiesterase that had obviously vasodilation on normal and pathology tissue [17][18][19][20][21]. The application of sildenafil and bosentan are essential to control the progress of pulmonary hypertension so they should not be stop in preoperative [22].…”

Section: Discussionmentioning

confidence: 99%

Anesthesia for a Patient with Severe Pulmonary Hypertension Undergoing Laparoscopic Cholecystectomy: A Case Report

Yi-lu¹,

Chen²,

Zhang³

et al. 2017

J Pulm Respir Med

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Anesthesia for a Patient with Severe Pulmonary Hypertension Undergoing Laparoscopic Cholecystectomy: A Case Report

Yi-lu¹,

Chen²,

Zhang³

et al. 2017

J Pulm Respir Med

View full text Add to dashboard Cite

“…There is genetic anticipation in familial PAH, i.e. the onset of disease occurs at an Indian Heart Journal 6401 (2012) [60][61][62][63][64][65][66][67][68][69][70][71][72][73] earlier age in successive generations. 8,9 Group 1 of Dana Point classification also includes drugs and toxins associated with development of PAH; the most notorious of these include the appetite suppressants fenfluramine and dexfenfluramine.…”

Section: Epidemiologymentioning

confidence: 99%

“…72 Similar results are reported in 20 patients in another study, also from India. 73 A much larger, double-blind, placebocontrolled randomised trial is reported in the New England Journal of Medicine in 2005. 74 In this multicentre Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) study, 278 symptomatic patients with PAH (idiopathic associated with connective tissue disease or with operated left-to-right shunts) were enrolled.…”

Section: Sildenafilmentioning

confidence: 99%

Pulmonary hypertension—“state of the art” management in 2012

Saxena

2012

Indian Heart Journal

View full text Add to dashboard Cite

A B S T R A C TPulmonary artery hypertension (PAH) is a pathological condition of small pulmonary arteries, characterised by vascular proliferation and remodelling. The pulmonary artery pressure and pulmonary vascular resistance progressively rise, leading to right heart failure and death. Pulmonary artery hypertension may be secondary to various conditions, or it may be idiopathic where no underlying cause is identifiable. Earlier, only symptomatic treatment was available for such patients which did not change the natural history of the disease. However, over the years, improvement in understanding the pathogenesis has resulted in the development of targeted approaches to the treatment of PAH. Survival advantage has also been shown with some of the pharmacologic agents. This review article discusses the current management strategy for PAH with special emphasis on an idiopathic variety, in an Indian context.

show abstract

“…56 These findings are supported by other small studies of PDE-5 inhibitors, alone and in combination with prostanoids, which also showed improvements in exercise capacity, functional class and some hemodynamic parameters without safety issues. [57][58][59][60] Recently, Tay et al showed that 3 months sildenafil was well tolerated in 12 adult ES and associated with a significant improvement in quality of life and exercise capacity. 61 Results with regard to efficacy, although encouraging, need validation in large randomised, placebo-controlled trials.…”

Section: Conventional Managementmentioning

confidence: 99%